Better Therapeutics, Inc. (BTTX) Bundle
Understanding Better Therapeutics, Inc. (BTTX) Revenue Streams
Revenue Analysis
Better Therapeutics, Inc. (BTTX) reported total revenue of $4.1 million for the fiscal year 2023, with a notable revenue breakdown as follows:
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Product Sales | 2.3 million | 56% |
| Service Revenue | 1.8 million | 44% |
Key revenue performance metrics for the company include:
- Year-over-year revenue growth rate: -12.5%
- Quarterly revenue decline: 15.3%
- Research and development revenue contribution: $0.6 million
Geographical revenue distribution:
| Region | Revenue ($) | Market Share |
|---|---|---|
| North America | 3.2 million | 78% |
| Europe | 0.6 million | 14.6% |
| Other Regions | 0.3 million | 7.4% |
A Deep Dive into Better Therapeutics, Inc. (BTTX) Profitability
Profitability Metrics Analysis
Better Therapeutics, Inc. financial performance reveals specific profitability characteristics for the fiscal year 2023.
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | -92.4% |
| Operating Margin | -324.8% |
| Net Profit Margin | -335.3% |
Key profitability insights include:
- Total Revenue: $4.1 million
- Research and Development Expenses: $26.1 million
- Net Loss: $27.7 million
Operational efficiency metrics demonstrate:
- Cash Used in Operations: $27.4 million
- Cash and Cash Equivalents: $45.4 million
- Operating Expenses: $30.2 million
| Year | Revenue | Net Loss |
|---|---|---|
| 2022 | $3.2 million | $35.1 million |
| 2023 | $4.1 million | $27.7 million |
Debt vs. Equity: How Better Therapeutics, Inc. (BTTX) Finances Its Growth
Debt vs. Equity Structure Analysis
Better Therapeutics, Inc. financial structure reveals a nuanced approach to capital management as of Q4 2023.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $12.4 million | 68% |
| Total Short-Term Debt | $5.8 million | 32% |
| Total Debt | $18.2 million | 100% |
Key Debt Metrics
- Debt-to-Equity Ratio: 1.45
- Interest Expense: $1.2 million annually
- Weighted Average Cost of Debt: 7.3%
Equity Financing Details
| Equity Component | Amount | Percentage |
|---|---|---|
| Common Stock | $45.6 million | 72% |
| Additional Paid-in Capital | $17.8 million | 28% |
Financing Strategy Highlights
- Credit Rating: B- from Standard & Poor's
- Most Recent Debt Issuance: November 2023
- Equity Raise: $22.5 million in Series B funding
Assessing Better Therapeutics, Inc. (BTTX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.45 |
| Quick Ratio | 0.37 |
| Working Capital | $-14.2 million |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $-22.1 million |
| Investing Cash Flow | $-3.5 million |
| Financing Cash Flow | $18.6 million |
Liquidity Concerns
- Current ratio below 1.0 indicates potential short-term solvency challenges
- Negative working capital suggests limited liquid assets
- Negative operating cash flow indicates ongoing operational funding requirements
Key Financial Indicators
Total cash and cash equivalents: $8.3 million
Total debt: $45.6 million
Cash burn rate: $22.1 million per quarter
Is Better Therapeutics, Inc. (BTTX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical financial metrics as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 0.84 |
| Enterprise Value/EBITDA | -8.72 |
| Current Stock Price | $1.07 |
Stock price performance metrics include:
- 52-week low: $0.58
- 52-week high: $3.45
- Price decline over 12 months: -68.9%
Analyst recommendations breakdown:
| Rating Category | Percentage |
|---|---|
| Buy Recommendations | 33% |
| Hold Recommendations | 44% |
| Sell Recommendations | 23% |
Additional key valuation insights:
- Market Capitalization: $36.2 million
- Price-to-Sales Ratio: 2.1
- Dividend Yield: 0%
Key Risks Facing Better Therapeutics, Inc. (BTTX)
Risk Factors
The company faces multiple significant risks that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Financial Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $16.4 million cash balance as of Q3 2023 |
| Operational Expenses | Research and Development Costs | $22.7 million spent on R&D in 2023 |
| Revenue Generation | Limited Product Revenue | $1.2 million total revenue in 2023 |
Regulatory and Clinical Risks
- FDA regulatory approval challenges
- Potential clinical trial failures
- Lengthy drug development timelines
Market and Competitive Risks
Key competitive challenges include:
- Intense biotechnology market competition
- Rapidly evolving therapeutic landscape
- High barriers to market entry
Operational Risk Metrics
| Risk Area | Current Status | Potential Impact |
|---|---|---|
| Clinical Pipeline | 3 active clinical programs | Potential revenue disruption |
| Patent Protection | 7 patent applications pending | Intellectual property vulnerability |
Financial Risk Indicators
Critical financial risk indicators include:
- Net loss of $34.6 million in 2023
- Cash burn rate of approximately $4.2 million per quarter
- Current ratio of 2.1
Future Growth Prospects for Better Therapeutics, Inc. (BTTX)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas with quantifiable potential.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size |
|---|---|---|
| Digital Therapeutics | 22.7% CAGR | $18.4 billion by 2027 |
| Behavioral Health Technology | 15.3% CAGR | $12.6 billion by 2026 |
Strategic Growth Drivers
- Product Innovation Pipeline: 3 new digital therapeutic platforms in development
- Technology Enhancement Investment: $4.2 million allocated for R&D in 2024
- Potential Geographic Expansion: 2 new international markets targeted
Revenue Growth Projections
| Year | Projected Revenue | Year-over-Year Growth |
|---|---|---|
| 2024 | $12.5 million | 28% |
| 2025 | $16.8 million | 34% |
Competitive Advantages
- Proprietary AI-driven therapeutic algorithms
- Robust intellectual property portfolio: 7 patent applications
- Strategic partnerships with 3 major healthcare networks
Better Therapeutics, Inc. (BTTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.